$100 minimum and no way BMY steps in with that kind of dosh now prior to phase II completion of the combination trials. Celldex is definitely worth it and they know it's the brother of Medarex that gave them their blockbuster cancer therapy, but they still won't (can't) jump in yet. Plus, AM and company don't want another buyout for cash- they already have that done, they are planning to be the future kings of the immunotherapy biotech arena. That's going to take more effort, but has upside of an order of magnitude. Company is Not For Sale!